JP2019526270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526270A5 JP2019526270A5 JP2019513999A JP2019513999A JP2019526270A5 JP 2019526270 A5 JP2019526270 A5 JP 2019526270A5 JP 2019513999 A JP2019513999 A JP 2019513999A JP 2019513999 A JP2019513999 A JP 2019513999A JP 2019526270 A5 JP2019526270 A5 JP 2019526270A5
- Authority
- JP
- Japan
- Prior art keywords
- bcr
- nucleic acid
- acid encoding
- primary
- therapeutic cassette
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022162584A JP2022189863A (ja) | 2016-09-12 | 2022-10-07 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
| JP2025171949A JP2025188209A (ja) | 2016-09-12 | 2025-10-10 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393512P | 2016-09-12 | 2016-09-12 | |
| US62/393,512 | 2016-09-12 | ||
| PCT/US2017/051182 WO2018049401A1 (en) | 2016-09-12 | 2017-09-12 | Genome edited primary b cell and methods of making and using |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162584A Division JP2022189863A (ja) | 2016-09-12 | 2022-10-07 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019526270A JP2019526270A (ja) | 2019-09-19 |
| JP2019526270A5 true JP2019526270A5 (https=) | 2020-10-22 |
Family
ID=61562180
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513999A Withdrawn JP2019526270A (ja) | 2016-09-12 | 2017-09-12 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
| JP2022162584A Pending JP2022189863A (ja) | 2016-09-12 | 2022-10-07 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
| JP2025171949A Pending JP2025188209A (ja) | 2016-09-12 | 2025-10-10 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162584A Pending JP2022189863A (ja) | 2016-09-12 | 2022-10-07 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
| JP2025171949A Pending JP2025188209A (ja) | 2016-09-12 | 2025-10-10 | ゲノム編集初代ｂ細胞ならびに作製方法および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220168342A1 (https=) |
| EP (1) | EP3509606A4 (https=) |
| JP (3) | JP2019526270A (https=) |
| CN (1) | CN109843303A (https=) |
| AU (1) | AU2017322733B2 (https=) |
| CA (1) | CA3036820A1 (https=) |
| NZ (1) | NZ751836A (https=) |
| WO (1) | WO2018049401A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11939594B2 (en) | 2017-03-16 | 2024-03-26 | Seattle Children's Hospital | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins |
| JP7698321B2 (ja) * | 2019-11-27 | 2025-06-25 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｂ細胞のｃａｒ形質導入とｃｒｉｓｐｒ遺伝子編集との大規模での組み合わせ |
| US20240384304A1 (en) * | 2021-07-06 | 2024-11-21 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
| US20240352420A1 (en) * | 2021-07-29 | 2024-10-24 | Regents Of The University Of Minnesota | Multiplex base editing of primary human natural killer cells |
| WO2024015925A2 (en) * | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| WO2024196669A2 (en) * | 2023-03-17 | 2024-09-26 | Walking Fish Therapeutics, Inc. | Methods for in vivo editing of b cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017533729A (ja) * | 2014-10-24 | 2017-11-16 | ベーセーエルテー ホールディングス ベーフェー | Ｔ細胞ベースの免疫療法薬 |
| DK3234107T3 (da) * | 2014-12-19 | 2022-10-17 | Immusoft Corp | B-celler til in vivo-levering af terapeutiske midler |
| AU2016243052C1 (en) * | 2015-04-03 | 2022-11-24 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of B-cells |
-
2017
- 2017-09-12 JP JP2019513999A patent/JP2019526270A/ja not_active Withdrawn
- 2017-09-12 AU AU2017322733A patent/AU2017322733B2/en active Active
- 2017-09-12 US US16/332,555 patent/US20220168342A1/en active Pending
- 2017-09-12 NZ NZ751836A patent/NZ751836A/en unknown
- 2017-09-12 CN CN201780059655.8A patent/CN109843303A/zh active Pending
- 2017-09-12 CA CA3036820A patent/CA3036820A1/en active Pending
- 2017-09-12 EP EP17849776.4A patent/EP3509606A4/en active Pending
- 2017-09-12 WO PCT/US2017/051182 patent/WO2018049401A1/en not_active Ceased
-
2022
- 2022-10-07 JP JP2022162584A patent/JP2022189863A/ja active Pending
-
2025
- 2025-10-10 JP JP2025171949A patent/JP2025188209A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526270A5 (https=) | ||
| WO2015112626A8 (en) | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules | |
| MX2022015821A (es) | Nuevos receptores de celulas t y usos de los mismos. | |
| CY1123028T1 (el) | Σταθερα και διαλυτα αντισωματα που αναστελλουν τον vegf | |
| JOP20200091A1 (ar) | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري | |
| CA3045233A1 (en) | Novel t cell receptors and immune therapy using the same | |
| JP2010227108A5 (https=) | ||
| CL2013001124A1 (es) | Anticuerpo aislado o una proteína que comprende una porción de enlace de antígeno de un anticuerpo dirigido contra un polipéptido de cd40; composicion farmacéutica que comprende dicho anticuerpo; ácido nucleico que codifica el anticuerpo; vector de clonación; proceso de producción del anticuerpo. | |
| JP2012126742A5 (https=) | ||
| CN109790222A (zh) | 抗密蛋白18a2的抗体及其应用 | |
| PH12018502544A1 (en) | Antibody for binding to interleukin 4 receptor | |
| JP2011155981A5 (https=) | ||
| WO2018104909A3 (en) | Dna methylation profiling for t-cell immunotherapy | |
| BR112013018311A2 (pt) | sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada. | |
| JP2017534262A5 (https=) | ||
| BR112017014031A2 (pt) | n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado. | |
| EA202091166A1 (ru) | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ | |
| JP2011152135A5 (https=) | ||
| JP2016510594A5 (https=) | ||
| JP2013539454A5 (https=) | ||
| WO2015112749A3 (en) | Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy | |
| FI3792628T3 (fi) | Menetelmiä neoantigeenien hyödyllisyyden ennustamiseen immunoterapiassa | |
| JP2018023397A5 (https=) | ||
| EA201100674A1 (ru) | Вакцина против вируса африканской чумы лошадей | |
| HRP20230605T1 (hr) | Protutijela protiv interferona beta i njihova upotreba |